aView · LCS
Axial · Slice 147/320 · W:1500 L:-600
LungAI v2.4
~10 mm
Lung-RADS
4X
Highly Suspicious
Malignancy Risk
87/100
High Risk
+1.8 mm vs prior
LungAI · Nodule #1
TypeSolid
Size10.2 × 8.4 mm
Volume384 mm³
Density+28 HU
MarginSpiculated
LocationLUL · periph
VDT240 d
Drag to compare
Workflow
Split view
Read time
5 to 10 min / ~2 min
Output
Category + Score
Billable (Post FDA Clearance)
Standard fees + CPT 0721T · $650
Drag the divider to compare a manual Lung-RADS read with LungAI CADx on the same scan. Investigational Device: Not FDA Cleared. For Demonstrative Purposes Only.
AI-Powered Lung Cancer Screening
Every Radiologist Deserves an
AI Lung Cancer Screening 2nd Opinion.
In retrospective testing using held-out NLST data, LungAI's malignancy-risk model demonstrated improvements in AUROC, sensitivity, specificity and precision when evaluated alongside Lung-RADS v2022. LungAI has not been prospectively validated for clinical use.
0.96
AUROC, retrospective held-out NLST dataset.
100M
Parameter
Vision Transformer
Vision Transformer
CPT 0721T/scan
Reimbursable under HOPPS, following FDA clearance
The reality of lung cancer in America
The numbers that make early detection urgent
131,880
Americans die from lung cancer every year, more than breast, colon, and prostate combined
18%
Of eligible Americans are currently screened for lung cancer each year
85%
Of lung cancers are still diagnosed at late stage, when 5-year survival is under 9%
64.7%
5-year survival rate when lung cancer is caught early at Stage I or II
20-28M
Americans are eligible for free annual LDCT screening
<6%
Screened in underserved FQHC communities, where the gap is widest
Sources: ACS Cancer Facts 2024, USPSTF 2021, NLST, NCI SEER. Learn more about lung cancer screening →
Our Mission
Built from loss.
Driven by love.
Built to save lives.
Too many people, especially in underserved communities, are diagnosed with lung cancer too late. We built Oatmeal Health to change that.
“
I started Oatmeal Health for a simple reason. Cancer wasn't caught early in the people I loved, and it cost them their lives. I'm making sure others get caught in time.
How Oatmeal Health Works
From missed to detected.
From risk to care.
From risk to care.
A full-funnel platform that finds high-risk patients, guides them to screening, and delivers AI-powered malignancy risk scoring.
1
Identify
Finding eligible patients is the hardest part of any lung cancer screening program. Our AI mines EHR data to surface patients with 20+ pack-year smoking histories, even when that history is buried in clinical notes and never entered into structured fields.
2
Reach
Our AI-powered voice caller and nurse navigators reach patients via phone, text, and voicemail. They educate patients on their eligibility and screening options, then schedule a shared decision-making visit with the clinical team.
3
Screen
Patients access low-dose CT scans through our partner imaging network. We help schedule SDM visits and annual screenings so no eligible patient falls through the cracks or misses their follow-up.
4
Analyze
When cleared by the FDA, LungAI CADx will score every nodule 0 to 100 inside the radiologist's existing viewer. No new workstation, no new login. Results in under 3 minutes.
5
Act
Lung-RADS tells you the category. LungAI tells you the probability of cancer. Clinicians, post-FDA clearance, will use the score to fast-track high-risk cases, extend low-risk follow-ups to 3, 6, or 12 months, and stop treating borderline nodules like coin flips. The right patient gets the right next step.
Post-FDA 510(k) clearance, we plan to close the gap in care so every community gets a fair shot at life.
See our impact →
Who Benefits
Learn More →
Learn More →
Learn More →
Learn More →
Learn More →
Value for Every Stakeholder
LungAI is being developed to create measurable clinical and financial value at every point in the care pathway, for patients, radiologists, pulmonologists, CADe partners, and health plans.
Patients
A real chance at surviving lung cancer.
- Stage I survival 77 to 92% vs just 9% at Stage IV
- Higher sensitivity than Lung-RADS alone in retrospective testing
- Research objective: evaluate whether AI-assisted risk assessment can improve identification and risk stratification of suspicious pulmonary nodules and reduce the need for unnecessary biopsies
77–92%
5-year survival at Stage I vs 9% at Stage IV
Radiologists
Less cognitive burden. More confidence.
- Risk score appears inline, no new software, no extra clicks
- Read time drops from 5 to 10 min to 1.5 to 3 min
- 33 to 50% fewer unnecessary follow-up orders and biopsies (retrospective modeling; not established prospectively)
80%
In internal retrospective workflow testing, observed reading times were up to 80% shorter under the tested conditions.
Pulmonologists
Risk-stratify patients. Prioritize the ones who can't wait.
- Offer help with Biopsy vs wait decisions
- High-risk cases get priority appointment slots automatically
- May extend follow-up from 3 to 6 months, less radiation, fewer visits
0.96
AUROC: Retrospective performance: 0.96 AUROC on held-out NLST data
Hospitals and Health Systems
Screening revenue is just the beginning.
- Every screen generates downstream referrals: biopsy, PET/CT, surgery, oncology, all staying in-system
- Positions the health system as a lung cancer center of excellence in the community
- HEDIS quality uplift, community benefit reporting, and Stage I detection rate improvement
$1.4M
system-wide revenue per 1,000 screens (illustrative estimate)
Health Plans
$60M to $100M saved per 100 cases caught early (illustrative estimate).
- Stage I cost ~$200K vs Stage IV at ~$800K to $1.2M
- NCQA developing lung cancer screening HEDIS measure
- CPT 0721T pathway exists; LungAI billable only after FDA clearance
4–6x
ROI from early detection vs late-stage treatment
Applications Under Evaluation. Pre-FDA 510(k) clearance. NLST held-out retrospective study. Results may differ in prospective clinical use. CPT 0721T reimbursement figures reflect CMS 2025 Medicare rates. Commercial rates vary by payer and contract.
Our CEO's Story
A mission born from personal loss
After losing more than ten family members to cancer, Jonathan Govette founded Oatmeal Health to make sure fewer families have to endure the same. We built the platform we wish had existed.
Read our story →
"
We can defuse the cancer time bomb, but only if we find people earlier.
Jonathan Govette
CEO and Co-Founder
Get started
Ready to close the gap
in your community?
in your community?
Whether you run an FQHC or a hospital, we have a program built for you.